Immvira is developing oncolytic herpes simplex virus (oHSV) therapies to target and destroy cancer cells while sparing healthy tissue. Their approach aims to enhance treatment efficacy and improve patient outcomes in oncology by leveraging insights from experimental designs and clinical trial results.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer treatments often lack the ability to selectively target and destroy cancer cells, leading to damage of healthy tissues and potentially limiting treatment efficacy. This non-specific targeting can result in significant side effects and reduced quality of life for patients undergoing oncology therapies.
Solution
Immvira is developing oncolytic herpes simplex virus (oHSV) therapies engineered to selectively target and destroy cancer cells while sparing healthy tissue. These oHSV therapies are designed to replicate within cancer cells, leading to cell lysis and the release of tumor-associated antigens, which can stimulate an anti-tumor immune response. By leveraging insights from experimental designs and clinical trial results, Immvira aims to enhance treatment efficacy and improve patient outcomes in oncology. The company's approach seeks to provide a more targeted and effective treatment option for cancer patients, minimizing off-target effects and maximizing the therapeutic benefit.
Target Audience
Immvira's primary target audience includes oncology researchers and clinicians seeking more effective and targeted cancer therapies, as well as pharmaceutical companies interested in developing novel oncolytic virus-based treatments.
Features
- Oncolytic herpes simplex virus (oHSV) platform for targeted cancer cell destruction
- Selective replication within cancer cells to minimize damage to healthy tissue
- Induction of anti-tumor immune response through release of tumor-associated antigens
- Development informed by experimental designs and clinical trial results